Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Alteplase Clear all
Withdrawn Not applicable Interventional

Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients

NCT00780377
View directory record Official record
Conditions
Heart Transplantation
Interventions
Bradykinin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 15, 2026, 10:58 AM EDT
Completed Not applicable Interventional Results available

Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial

NCT01657461
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Solitaire revascularization device
Drug · Device
Lead sponsor
Medtronic Neurovascular Clinical Affairs
Industry
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 15, 2026, 10:58 AM EDT
Withdrawn Phase 1 Interventional

Study for the Use of Alteplase in Patients Who Awaken With Stroke

NCT01150266
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Alteplase (tPA)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 15, 2026, 10:58 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

NCT03594175
View directory record Official record
Conditions
Catheter Occlusion, Thrombosis
Interventions
CUSA-081, Placebo, Alteplase
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Little Rock, Arkansas • Redlands, California • Stockton, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 15, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins

NCT00082355
View directory record Official record
Conditions
Acute Deep Venous Thrombosis of the Lower Extremity
Interventions
Alteplase (Activase, Genentech)
Drug
Lead sponsor
Richard Chang, M.D.
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Sep 15, 2026, 10:58 AM EDT
Recruiting Phase 2Phase 3 Interventional

Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial

NCT06949228
View directory record Official record
Conditions
Ischemic Stroke, Acute Disease
Interventions
tenecteplase
Drug
Lead sponsor
ProMedica Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 15, 2026, 10:58 AM EDT
Recruiting Phase 2 Interventional

Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections [LYTICS +]

NCT06713382
View directory record Official record
Conditions
Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion Disorder, Pleural Effusions
Interventions
Pleural Saline Irrigation
Combination Product
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 15, 2026, 10:58 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants

NCT00265005
View directory record Official record
Conditions
Thrombosis
Interventions
alteplase
Drug
Lead sponsor
University of Louisville
Other
Eligibility
28 Weeks to 66 Weeks
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 15, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

NCT01827046
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
rt-PA
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Carmichael, California + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Sep 15, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses

NCT00284739
View directory record Official record
Conditions
Abdominal Abscess, Pelvic Abscess
Interventions
Alteplase, saline
Drug · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Sep 15, 2026, 10:58 AM EDT
Not listed Phase 2 Interventional

Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention

NCT01455935
View directory record Official record
Conditions
Stroke
Interventions
Anti-platelets and statin, alteplase, intra arterial intervention
Drug · Procedure
Lead sponsor
Jacobs Neurological Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 15, 2026, 10:58 AM EDT
Completed Not applicable Interventional Results available

Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy

NCT01197573
View directory record Official record
Conditions
Liver Transplantation, Kidney Transplantation
Interventions
rTPA Treatment, No TPA Treatment
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 15, 2026, 10:58 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Synergistic Minimally Invasive Surgery and Deferoxamine in ICH

NCT07162363
View directory record Official record
Conditions
Intracerebral Hemorrhage, ICH - Intracerebral Hemorrhage
Interventions
Minimally Invasive surgery (MIS), Deferoxamine, Standard Medical Care (SMD)
Procedure · Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Sep 15, 2026, 10:58 AM EDT
Not listed Phase 1 Interventional

Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions

NCT02135588
View directory record Official record
Conditions
Loculated or Non-draining Malignant Pleural Effusions
Interventions
Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)
Drug
Lead sponsor
Eastern Regional Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 15, 2026, 10:58 AM EDT
Terminated Phase 1Phase 2 Interventional

Transcranial Ultrasound in Clinical SONothrombolysis

NCT00504842
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
MRX-801, Placebo
Drug
Lead sponsor
ImaRx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2008 · Synced Sep 15, 2026, 10:58 AM EDT
Terminated Phase 4 Interventional Results available

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

NCT03988842
View directory record Official record
Conditions
Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction, Pulmonary Embolism Subacute Massive, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions
Alteplase, Unfractionated heparin, Placebo, Apixaban
Drug
Lead sponsor
Victor Tapson, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 15, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

NCT00790335
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism, Post Thrombotic Syndrome
Interventions
Recombinant tissue plasminogen activator (rt-PA)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
16 Years to 75 Years
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
56
States / cities
Glendale, Arizona • Orange, California • Stanford, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 15, 2026, 10:58 AM EDT
Withdrawn Not applicable Interventional

Brachial Artery t-PA Release in Heart Transplant Recipients

NCT00780637
View directory record Official record
Conditions
Heart Transplantation
Interventions
Bradykinin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 15, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection

NCT03672006
View directory record Official record
Conditions
Central Venous Catheter Thrombosis, Central Venous Catheter Associated Bloodstream Infection
Interventions
alteplase (recombinant t-PA), Heparin
Biological · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 15, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III

NCT00784134
View directory record Official record
Conditions
Intraventricular Hemorrhage
Interventions
Alteplase, Normal saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 15, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy

NCT01513759
View directory record Official record
Conditions
Pulmonary Embolism, Acute Pulmonary Embolism, Sub-massive Pulmonary Embolism, Massive Pulmonary Embolism, Pulmonary Thromboembolism
Interventions
recombinant tissue plasminogen activator, EKOS EkoSonic Endovascular System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
22
States / cities
Montgomery, Alabama • Modesto, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 15, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional

Evaluation of MST-188 in Acute Lower Limb Ischemia

NCT02093468
View directory record Official record
Conditions
Acute Limb Ischemia
Interventions
MST-188, Saline
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
4
States / cities
Little Rock, Arkansas • Tampa, Florida • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 15, 2026, 10:58 AM EDT
Terminated Phase 3 Interventional

Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke

NCT01098981
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Transcranial ultrasound as an adjunctive therapy to tPA, Standard of care tPA therapy for acute ischemic stroke
Device · Drug
Lead sponsor
Cerevast Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 15, 2026, 10:58 AM EDT
Suspended No phase listed Observational

Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE

NCT06310018
View directory record Official record
Conditions
Pulmonary Embolism, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions
Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis, Tissue Plasminogen Activator
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 15, 2026, 10:58 AM EDT